Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

PHASE2RecruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

September 30, 2025

Conditions
Immune ThrombocytopeniaAutoantibodiesEvan SyndromeConnective Tissue Diseases
Interventions
DRUG

Avatrombopag

The subjects will receive avatrombopag treatment with an initial dose of 40mg once a day. Platelet counts will be obtained weekly during the first 4 weeks and then every 2 weeks until week 12 after treatment. The dose adjustment range is 20 mg per week to 40 mg per day to maintain the platelet level between 30×10\^9/L and 200×10\^9/L. If the platelet count does not reach to 30×10\^9/L after taking avatrombopag 40mg once a day for 4 consecutive weeks, the treatment will be stopped.

Trial Locations (1)

300020

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER